natgillin/translations-raw huggingface dataset:
The rationale for prescription should be tailored to the individual needs of the cat, based on clinical assessment, the animal’s lifestyle and on the local epidemiological situation (including zoonotic risks, where relevant) in order to address exclusively situations of mixed infestations/risk of infestation.
Odluka o propisivanju se temelji na procjeni veterinara i mora biti prilagođena lokalnoj epizootiološkoj situaciji.
The rationale for prescription should be tailored to the individual needs of the cat, based on clinical assessment, the animal’s lifestyle and on the local epidemiological situation (including zoonotic risks, where relevant) in order to address exclusively situations of mixed infestations/risk of infestation.
Odluku o propisivanju treba uskladiti s individualnim potrebama mačke, temeljenu na kliničkoj slici, načinu života i lokalnoj epidemiološkoj situaciji (uključujući zoonotski rizik, ukoliko je bitno) isključivo u cilju rješavanja mješovitih infestacija/rizika od infestacija.
The ratios (13 to 17 years/Adults) for AUC, the end of infusion concentration and the concentration at the midpoint of the dosing interval were 0.99, 1.20, and 0.84, respectively.
Omjer između skupine ispitanika od 13 do 17 godina i odraslih iznosio je 0,99 za AUC, 1,20 za koncentraciju na kraju infuzije te 0,84 za koncentraciju na polovici intervala doziranja.
The ratios of geometric least-square means of month 6-to-baseline pharmacokinetic were 107%, 100% and 104% for recovery, AUCt and AUC, respectively.
Omjeri geometrijskih srednjih vrijednosti najmanjih kvadrata farmakokinetičkih parametara u 6. mjesecu naspram početnih iznosili su 107%, 100% za AUCt i 104% za povrat, AUCt i AUC.
The ratios of geometric least-square means of ReFacto AF-to-ReFacto were 100.6%, 99.5% and 98.1% for recovery, AUCt and AUC∞ (area under the plasma concentration curve from time zero to infinity), respectively.
Omjeri geometrijskih srednjih vrijednosti najmanjih kvadrata za ReFacto AF i ReFacto iznosili su 100,6%, 99,5% za AUCt i 98,1% za povrat, AUCt, AUC∞ (površina ispod krivulje koncentracije u plazmi od vremena nula do beskonačno).
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH 9)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
Omjer glavnog metabolita M1 (des-(Orn8, Gly- NH 9)-[Mpa1, D-Tyr(Et)2, Thr4]-oksitocin) prema koncentraciji atosibana u plazmi iznosio je 1,4 odnosno 2,8 nakon dva sata i na kraju infuzije.
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
Omjer glavnog metabolita M1 (des-(Orn8, Gly- NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oksitocin) prema koncentraciji atosibana u plazmi iznosio je 1,4 odnosno 2,8 nakon dva sata i na kraju infuzije.
The RE-LY extension study (RELY-ABLE) provided additional safety information for a cohort of patients which continued the same dose of dabigatran etexilate as assigned in the RE-LY trial.
Produžetak ispitivanja RE-LY (RELY-ABLE) pružio je dodatne sigurnosneinformacije za kohortu bolesnika koja je nastavila primati jednaku dozu dabigatraneteksilata kao onu koja im je bila određena u ispitivanju RE-LY.
The RE-LY study demonstrated that dabigatran etexilate, at a dose of 110 mg twice daily, is non-inferior to warfarin in the prevention of stroke and SEE in subjects with atrial fibrillation, with a reduced risk of ICH, total bleeding and major bleeding.
RE-LY studija pokazala je da je dabigatraneteksilat, u dozama od 110 mg dvaput dnevno, neinferioran varfarinu u prevenciji moždanog udara i SE-a u bolesnika s fibrilacijom atrija te da je rizik ICH, ukupnog krvarenja i velikog krvarenja niži.
The reaction is maximal at 2–3 days post vaccination with a maximum area of 3 cm by 8 cm.
Ta reakcija traje najviše 2-3 dana nakon cijepljenja s najvećim područjem od 3 cm do 8 cm.
The reaction reduced and disappeared without need for treatment.
Reakcija se postupno smanjila te se spontano povukla bez potrebe za liječenjem.
The reaction reduces and disappears without need for treatment.
Reakcija se postupno smanjuje te se spontano povuče bez potrebe za liječenjem.
The reactions are listed below as MedDRA preferred term by system organ class and absolute frequency.
Nuspojave su navedene preporučenim MedDRA izrazima i prema organskim sustavima i apsolutnoj učestalosti.
The reactions included injection site erythema, injection site haematoma and injection site pain (see also section 5.3).
Reakcije su uključivale eritem na mjestu primjene injekcije, hematom na mjestu primjene injekcije i bol na mjestu primjene injekcije (vidjeti također dio 5.3).
The reactions may persist for at least 97 days in the form of small granules of less than 0.5 cm of diameter.
Reakcije u obliku malih granula koje su u promjeru manje od 0,5 cm, mogu trajati minimalno 97 dana.
The reactions normally disappear after a few hours when you remove the patch.
Te promjene obično nestanu nekoliko sati nakon odstranjenja flastera.
The reactions normally disappear after a few hours when you remove the patch.
Te promjene obično spontano nestanu par sati po odstranjivanju flastera.
The reactions reported were usually reversible with a reduction in rate, or interruption, of MabThera infusion and administration of an anti-pyretic, an antihistamine, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required.
Prijavljene reakcije obično su se povukle nakon smanjenja brzine infuzije ili prekida infuzije lijeka MabThera te primjene antipiretika, antihistaminika i povremeno kisika, intravenske primjene fiziološke otopine ili bronhodilatatora te, po potrebi, glukokortikoida.
The reactogenicity profile and rates of adverse events among subjects aged 56-65 years who received Menveo (N=216), were similar to that observed in Menveo recipients subjects aged 11-55.
Profil reaktogenosti i stope nuspojava u ispitanika u dobi od 56 do 65 godina koji su primali Menveo (N=216) bili su slični onima uočenim u ispitanika u dobi od 11 do 55 godina koji su primali Menveo.
The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre- haemodialysis and haemodialysis patients.
Profil reaktogenosti cjepiva Fendrix kod zdravih ispitanika općenito je bio usporediv s onim zamijećenim kod bolesnika pred hemodijalizom i onih na hemodijalizi.
The readily prepared Zoledronic acid medac infusion solution should preferably be used immediately.
Pripremljenu otopinu za infuziju Zoledronatne kiseline medac treba po mogućnosti odmah primijeniti.
The readily prepared Zoledronic Acid Teva infusion solution should preferably be used immediately.
Pripremljenu otopinu za infuziju Zoledronatne kiseline Teva treba po mogućnosti odmah primijeniti.
The readout for PT is to be done in seconds, because the INR (International Normalised Ratio) is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.
Očitanja PV-a valja obaviti u sekundama jer je INR (International Normalized Ratio, međunarodni normalizirani omjer) kalibriran i validiran samo za kumarine i ne može se koristiti za bilo koji drugi antikoagulans.
The ready-to-use Ventavis nebuliser solution is administered with a suitable inhalation device (nebuliser) (see below and section 6.6).
Spremna za upotrebu, otopina za atomizator Ventavis primjenjuje se s odgovarajućim uređajem za inhalaciju (atomizatorom) (vidjeti niže i dio 6.6).
The reason for the reduced clinical efficacy observed in these patients is unknown.
Nije poznat uzrok smanjene kliničke djelotvornosti opažene kod ovih bolesnika.
The Rebif initiation packs correspond to the patient needs for the first month of treatment.
Početno pakiranje lijeka Rebif odgovara bolesnikovim potrebama za prvi mjesec liječenja.
The reclosable bottle cap should be discarded when the bottle is empty or after 3 days following opening even if the bottle is not empty.
Nastavak za bocu s čepom za ponovno zatvaranje treba baciti kad se bočica isprazni ili 3 dana nakon otvaranja, čak i ako bočica nije prazna.
The recombinant factor IX portion is identical to the Thr148 allelic form of plasma- derived factor IX.
Dio koji čini rekombinantni faktor IX identičan je alelnom obliku Thr148 faktora IX dobivenog iz plazme.
The recombinant human hyaluronidase should be clear and colourless.
Rekombinantna ljudska hijaluronidaza mora biti bistra i bezbojna.
The recommend dose of Pemetrexed medac is 500 mg for every square metre of your body’s surface area.
Preporučena doza lijeka Pemetrexed medac je 500 mg po svakom kvadratnom metru Vaše površine tijela.
The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).
Preporuka za uzimanje 15 mg temelji se na farmakokinetičkom modelu i nije ispitivana u ovom kliničkim uvjetima (vidjeti dijelove 4.4, 5.1 i 5.2).
The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).
Preporuka za uzimanje 15 mg temelji se na farmakokinetičkom modelu i nije ispitivana u ovom kliničkim uvjetima (vidjeti dijelove 4.4., 5.1. i 5.2.).
The recommendation of a minimum yield of 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Preporuka o minimalnom prinosu od 2,0 x 106 CD34+ stanica/kg temelji se na dosad objavljenim iskustvima, u kojima se postigla primjerena hematološka rekonstitucija.
The recommendation of a minimum yield of ≥ 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Preporuka o minimalnom prinosu od ≥ 2,0 x 106 CD34+ stanica/kg temelji se na dosad objavljenim iskustvima u postizanju primjerene hematološke rekonstitucije.
The recommendation of a minimum yield of ≥ 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Preporučeni najmanji prinos od ≥ 2,0 x 106 CD34+ stanica/kg temelji se na opisanom iskustvu koje je dovelo do odgovarajućeg hematološkog oporavka.
The recommendation that patients should have MRI scans at the following times:
Preporuka za snimanje bolesnika MR-om po sljedećem rasporedu:
The recommendations for darunavir boosted with ritonavir are adequate also for darunavir boosted with cobicistat with regard to substrates of CYP3A4, CYP2D6, P-glycoprotein, OATP1B1 and OATP1B3 (see contraindications and recommendations presented in the section above).
Preporuke za darunavir pojačan s ritonavirom vezano uz supstrate CYP3A4, CYP2D6, P glikoproteina, OATP1B1 i OATP1B3 primjenjive su također za darunavir pojačan s kobicistatom (vidjeti kontraindikacije i preporuke navedene u odjeljku iznad).
The recommendations provided under “Clinical comment” in Table 1 are based on drug interaction studies, clinical relevance, or predicted interactions due to elimination pathways.
Preporuke navedene pod naslovom "Klinička napomena" u tablici 1 temelje se na ispitivanjima interakcija, kliničkoj važnosti ili očekivanim interakcijama zbog puteva eliminacije.
The recommended activity for an adult is 185 MBq of flutemetamol (18F) administered intravenously (as a bolus within approximately 40 seconds).
Preporučena aktivnost za odraslu osobu iznosi 185 MBq flutemetamola (18F) primijenjena intravenski (kao bolus unutar otprilike 40 sekundi).
The recommended activity of technetium (99mTc) besilesomab should be between 400 MBq and 800 MBq.
Preporučena aktivnost tehnecijevog (99mTc) besilesomaba treba biti između 400 MBq i 800 MBq.
The recommended adult dose is:
Preporučena doza za odrasle je:
The recommended adult dose:
Preporučena doza za odrasle
The recommended and maximum dose is 0.5 mg/kg/week and should not be exceeded.
Preporučena i maksimalna doza je 0,5 mg/kg tjedno i ne smije se prekoračiti.
The recommended course of Rienso is based on the patient’s pre-treatment haemoglobin and body weight as provided in Table 1.
Preporučeni tijek liječenja lijekom Rienso temelji se na vrijednosti hemoglobina prije liječenja i tjelesnoj težini bolesnika, kako je prikazano u tablici 1.
The recommended course of treatment is 3 doses at approximately 2 week intervals.
Preporučeni protokol liječenja uključuje 3 doze u intervalima od otprilike 2 tjedna.
The recommended course of treatment is 3 doses at approximately 2-week intervals.
Preporučeni protkol liječenja uključuje 3 doze u intervalima od otprilike 2 tjedna.
The recommended daily dose is 12°capsules (3°g of the active ingredient) taken as 2°separate doses.
Preporučena dnevna doza je 12 kapsula (3 g djelatne tvari) koje se uzimaju u 2 odvojene doze.
The recommended daily dose is 20mg once a day.
Preporučena dnevna doza je 20 mg jedanput na dan.
The recommended daily dose is 4°tablets (2°g of the active ingredient) taken as 2°separate doses.
Preporučena dnevna doza je 4 tablete (2 g djelatne tvari) koje se uzimaju u 2 odvojene doze.
The recommended daily dose is 6 to 8 mg per kg for a child with a body weight of up to 55 kg or 300 to 500 mg for a child with a body weight more than 55 kg (which ever dose is lower) taken once a day.
Preporučena je dnevna doza od 6 mg do 8 mg po kilogramu za djecu tjelesne težine do 55 kg ili od 300 do 500 mg za djecu tjelesne težine iznad 55 kg (koja god je doza niža), a uzima se jedanput na dan.
The recommended daily dose is between 300 mg and 500 mg.
Preporučena je dnevna doza između 300 mg i 500 mg.
The recommended daily dose is Rivastigmine 3M Health Care Ltd.
Preporučena dnevna doza je Rivastigmin 3M Health Care Ltd.
The recommended daily dose of 12.5 mg/kg body weight corresponds to the Maximum Tolerated Dose (MTD).
Preporučena dnevna doza od 12.5 mg/kg tjelesne težine odgovara najvišoj podnošljivoj dozi (Maximum Tolerated Dose – MTD).
The recommended daily dose of Esbriet for patients with IPF is three 267 mg capsules three times a day with food for a total of 2403 mg/day.
Preporučena dnevna doza lijeka Esbriet u bolesnika s IPF-om je tri kapsule od 267 mg triput na dan s hranom, što čini ukupnu dozu od 2403 mg/dan.
The recommended daily dose of Kisplyx is 18 mg once a day (one 10 mg capsule and two 4 mg capsules) in combination with one 5-mg tablet of everolimus once a day.
Preporučena dnevna doza Kisplyxa iznosi 18 mg jedanput na dan (jedna kapsula od 10 mg i dvije kapsule od 4 mg) u kombinaciji s jednom tabletom everolimusa od 5 mg jedanput na dan.
The recommended daily dose of lenvatinib is 24 mg (two 10 mg capsules and one 4 mg capsule) once daily.
Preporučena dnevna doza lenvatiniba je 24 mg (dvije kapsule od 10 mg i jedna kapsula od 4 mg), a uzima se jedanput na dan.
The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily following treatment with a parenteral anticoagulant for at least 5 days.
Preporučena dnevna doza Pradaxe je 300 mg uzeta u obliku jedne kapsule od 150 mg dvaput dnevno nakon liječenja parenteralnim antikoagulansom od najmanje 5 dana.
The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.
Preporučena dnevna doza Pradaxe je 300 mg uzeta u obliku jedne kapsule od 150 mg dvaput dnevno.
The recommended daily dose of Tarceva is 100 mg taken at least one hour before or two hours after the ingestion of food, in combination with gemcitabine (see the summary of product characteristics of gemcitabine for the pancreatic cancer indication).In patients who do not develop rash within the first 4
Preporučena dnevna doza lijeka Tarceva iznosi 100 mg i treba ju uzimati najmanje jedan sat prije ili dva sata nakon obroka, u kombinaciji s gemcitabinom (pogledajte sažetak opisa svojstava gemcitabina za indikaciju rak gušterače).
The recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments.
Preporučena početna dnevna doza iznosi 0,2 jedinice/kg, a zatim se doza prilagođava pojedinom bolesniku.
The recommended dosage and duration of Pegasys for both HBeAg-positive and HBeAg-negative chronic hepatitis B is 180 micrograms once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh.
Preporučena doza i trajanje liječenja lijekom Pegasys kako HBeAg-pozitivnog tako i HBeAg- negativnog kroničnog hepatitisa B iznosi 180 mikrograma jedanput tjedno tijekom 48 tjedana, primijenjenog supkutano u predjelu trbuha ili bedra.
The recommended dosage for adults, adolescents and children aged 3 years of age and older is a total of 2 injections of 0.5 ml each:
Preporučena doza za odrasle, adolescente i djecu u dobi od 3 i više godina je ukupno 2 injekcije, svaka od po 0,5 ml:
The recommended dosage for babies and children aged 2 months to < 3 years is a total of 2 injections of 0.25 ml each:
Preporučena doza za dojenčad i djecu u dobi od 2 mjeseca do < 3 godine je ukupno 2 injekcije, svaka od po 0,25 ml:
The recommended dosage is 1 ml of the veterinary medicinal product per ear once a day for five consecutive days.
Preporučena doza: 1 mL ovog VMP/u inficirano uho/dan/5 uzastopnih dana.
The recommended dosage is 1 ml of the veterinary medicinal product per infected ear once a day for five consecutive days.
Preporučena doza: 1 mL ovog VMP/inficirano uho/dan/5 uzastopnih dana.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm2 of affected skin per day.
Preporučena doza je 1,52 µg hidrokortizon aceponata / cm2 oboljele kože na dan.
The recommended dosage is 200 mg once daily for 6 days.
Preporučena doza je 200 mg jedanput na dan tijekom 6 dana.
The recommended dosage is 400 mg (one tablet) twice daily.
Preporučena doza je 400 mg (jedna tableta) dvaput na dan.
The recommended dosage is as follows:
Preporučena doza je sljedeća:
The recommended dosage is in the range 5 to 10 million IU administered subcutaneously three times a week (every other day) for a period of 4 to 6 months.
Preporučena doza kreće se u rasponu od 5 do 10 milijuna IU i daje se supkutano triput na tjedan (svaki drugi dan) tijekom 4 do 6 mjeseci.
The recommended dosage is one tablet (150 mg lamivudine/300 mg raltegravir) twice daily.
Preporučena doza je jedna tableta (150 mg lamivudina/300 mg raltegravira) dvaput na dan.
The recommended dosage of Kaletra is 230/57.5 mg/m2 twice daily taken with food, up to a maximum dose of 400/100 mg twice daily.
Preporučena doza lijeka Kaletra je 230/57,5 mg/m² dva puta dnevno uz jelo, do najveće doze od 400/100 mg dva puta dnevno.
The recommended dosage of Kaletra is 5 ml of oral solution (400/100 mg) twice daily taken with food.
Preporučena doza lijeka Kaletra je 5 ml oralne otopine (400/100 mg) dvaput na dan uz jelo.
The recommended dosage of Kepivance is 60 micrograms/kg/day, administered as an intravenous bolus injection for three consecutive days before and three consecutive days after myeloablative radiochemotherapy for a total of six doses.
Preporučena doza Kepivancea iznosi 60 mikrograma/kg/dan, primijenjena u obliku intravenske bolus injekcije kroz 3 uzastopna dana prije i 3 uzastopna dana nakon mijeloablativne radiokemoterapije, ukupno 6 doza.
The recommended dosage of Lamivudine Teva is 100 mg once daily.
Preporučena doza Lamivudina Teva je 100 mg jedanput na dan.
The recommended dosage of Norvir in children is 350 mg/m² by mouth twice daily and should not exceed 600 mg twice daily.
Preporučena doza lijeka Norvir u djece je 350 mg/m2 dva puta na dan kroz usta, a doza ne smije premašiti 600 mg dva puta na dan.
The recommended dosage of Norvir powder for suspension in children is 350 mg/m² by mouth twice daily and should not exceed 600 mg twice daily.
Preporučena doza Norvir praška za oralnu suspenziju u djece je 350 mg/m2 kroz usta dva puta na dan, a doza ne smije premašiti 600 mg dva puta na dan.
The recommended dosage of Norvir solution in children is 350 mg/m² by mouth twice daily and should not exceed 600 mg twice daily.
Preporučena doza lijeka Norvir u djece je 350 mg/m2 dva puta na dan kroz usta, a doza ne smije premašiti 600 mg dva puta na dan.
The recommended dosage of Norvir solution is 600 mg (7.5 ml) twice daily by mouth.
Preporučena doza Norvir otopine je 600 mg (7,5 ml) dva puta na dan kroz usta.
The recommended dosage of Oxyglobin is 30 ml/kg of body weight administered intravenously at a rate up to 10 ml/kg/hr.
Preporučena doza proizvoda Oxyglobin je 30 ml/kg težine primijenjeno intravenozno brzinom do 10 ml/kg/h.
The recommended dosage of Plegridy is 125 micrograms injected subcutaneously every 2 weeks (14 days).
Preporučena doza je 125 mikrograma primijenjenosupkutanom injekcijom svaka 2 tjedna (14 dana).
The recommended dosage of Plegridy is 125 micrograms injected subcutaneously every 2 weeks (14 days).
Preporučena doza Plegridyja je 125 mikrograma primijenjeno koje se primjenjuje supkutanom injekcijom svaka 2 tjedna (14 dana).
The recommended dosage of Plegridy is 125 micrograms injected subcutaneously every 2 weeks (14 days).
Preporučena doza Plegridyja je 125 mikrograma primijenjeno supkutanom injekcijom svaka 2 tjedna (14 dana).
The recommended dosage of Plegridy is 125 micrograms injected subcutaneously every 2 weeks (14 days).
Preporučena doza Plegridyja je 125 mikrograma primijenjenosupkutanom injekcijom svaka 2 tjedna (14 dana).
The recommended dosage regimen must be followed but not exceeded (see section 4.10).
Režim preporučenog doziranja mora se poštovati i ne smije se prekoračiti (vidi odjeljak 4.10).
The recommended dosage regimens based on age for paediatric patients with cSSTI are shown below.
U nastavku je prikazan preporučeni režim doziranja prema dobi za pedijatrijske bolesnike s kompliciranim infekcijama kože i mekog tkiva.
The recommended dosages for patients naïve to phenylbutyric acid and for patients switching from sodium phenylbutyrate to RAVICTI are different.
Preporučene doze za bolesnike koji prethodno nisu liječeni fenilbutiratnom kiselinom i za bolesnike koji prelaze s natrijevog fenilbutirata na RAVICTI se razlikuju.
The recommended dose
Preporučena doza je
The recommended dose adjustments do not apply to the haemodialysis indication.
Preporučene prilagodbe doze ne primjenjuju se kod indikacije za hemodijalizu.
The recommended dose and duration of ribavirin depends on patient’s weight and on the medicinal product that is used in combination.
Preporučena doza ribavirina i trajanje doziranja ovise o tjelesnoj težini bolesnika te o lijeku koji se primjenjuje u kombinaciji.
The recommended dose and duration of Ribavirin Teva depends on patient’s weight and on the medicinal product that is used in combination.
Preporučena doza i trajanje liječenja lijekom Ribavirin Teva ovise o tjelesnoj težini bolesnika i lijeku s kojim se Ribavirin Teva primjenjuje u kombinaciji.
The recommended dose and regimen of ONIVYDE is 80 mg/m2 intravenously over 90 minutes, followed by
Preporučena doza i režim liječenja lijekom ONIVYDE je 80 mg/m2 intravenski tijekom 90 minuta, nakon čega slijedi
The recommended dose and schedule is 1 ± 0.2 x 107 cells/kg given as an intravenous infusion at a time interval of 21-49 days from transplantation, in the absence of spontaneous immune reconstitution and/or development of graft-versus-host disease (GvHD).
Preporučena doza i raspored primjene je 1 ± 0,2 x 107 stanica/kg dano u obliku intravenske infuzije, između 21.-49. dana od transplantacije, u odsutnosti spontane imunološke rekonstitucije i/ili razvoja reakcije presatka protiv primatelja (GvHD, engl. graft-versus-host disease).
The recommended dose and schedule of administration is:
Preporučena doza i raspored primjene je sljedeći:
The recommended dose and schedule of administration is: fludarabine administered as a single daily one-hour infusion at 30 mg/m² for 5 consecutive days or 40 mg/m² for 4 consecutive days.
Preporučena doza i raspored primjene je sljedeći: fludarabin primijenjen kao jednosatna infuzija jednom dnevnom od 30 mg/m² 5 uzastopnih dana ili od 40 mg/m² 4 uzastopna dana.